Cerevel Therapeutics, Inc.
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 2018-01-01
- Employees
- -
- Market Cap
- $8.1B
- Website
- https://www.cerevel.com/
A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT05138653
- Locations
- πΊπΈ
Labcorp Drug Development, Dallas, Texas, United States
Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy Participants
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05123079
- Locations
- πΊπΈ
Celerion Inc., Tempe, Arizona, United States
Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05106309
- Locations
- πΊπΈ
Celerion Inc., Tempe, Arizona, United States
A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT04958031
- Locations
- πΊπΈ
Scottsdale, Arizona, Scottsdale, Arizona, United States
πΊπΈLittle Rock, Arkansas, Little Rock, Arkansas, United States
πΊπΈSan Diego, California, San Diego, California, United States
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT04787302
- Locations
- π§πͺ
UZ Leuven, Leuven, Belgium
πΊπΈMassachusetts General Hospital Translational and Clinical Research Centers, Boston, Massachusetts, United States
Open-label Trial in Parkinson's Disease (PD)
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 992
- Registration Number
- NCT04760769
- Locations
- πΊπΈ
Pheonix, Arizona, Phoenix, Arizona, United States
πΊπΈReseda, California, Reseda, California, United States
πΊπΈNaples, Florida, Naples, Florida, United States
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 105
- Registration Number
- NCT04686786
- Locations
- πΊπΈ
Little Rock, Arkansas, Little Rock, Arkansas, United States
πΊπΈJacksonville, Florida, Jacksonville, Florida, United States
πΊπΈLexington, Kentucky, Lexington, Kentucky, United States
A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT04592536
- Locations
- π³π±
Centre for Human Drug Research, Leiden, Zernikedreef 8, Netherlands
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 507
- Registration Number
- NCT04542499
- Locations
- πΊπΈ
Chicago, Illinois, Chicago, Illinois, United States
πΊπΈBoston, Massachusettes, Boston, Massachusetts, United States
πΊπΈCleveland, Ohio, Cleveland, Ohio, United States
A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2021-08-31
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04295642
- Locations
- πΊπΈ
CNS Network, Long Beach, California, United States
πΊπΈAtlanta Center for Medical Research, Atlanta, Georgia, United States